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Abstract 
Background: No consensus has been reached on prognostic value of serum concentration of β (beta) 
subunit of human chorionic gonadotropin (β-hCG) in treatment response to methotrexate in 
management of ectopic pregnancy. Therefore, the present study aimed to evaluate this subject through 
a systematic review and meta-analysis.  
Materials and Methods: An extensive literature search on online databases was performed. All 
studies performed on ectopic pregnancy patients treated by methotrexate from all age groups were 
included. After collecting data, random effect models were used to calculate the pooled standardized 
mean difference (SMD) of β-hCG level in treatment success and treatment failure groups. Finally, 
pooled performance screening characteristics of serum β-hCG level were assessed in different cut 
offs.  
Results: Finally, 51 articles were included in meta-analysis. Overall treatment success rate of 
methotrexate was 84% [95% confidence interval (CI): 84-85 percent]. A negative association was 
found between serum β-hCG level and the treatment response before intervention (SMD= -1.10, 95% 
CI: -1.39 to -0.88). In addition, pooled sensitivity, specificity, and prognostic odds ratio of β-hCG in 
the 2000 mIU/mL cut off were: 0.75 (0.65-0.82), 0.68 (0.58-0.82), and 6.0 (5.0-8.0), respectively.  
Conclusion: The present meta-analysis showed that serum β-hCG concentration before treatment 
could predict success of methotrexate in management of ectopic pregnancy.  
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1- INTRODUCTION 
Ectopic pregnancy (EP) is a major 
public health problem worldwide and its 
incidence has been increasing recently (1, 
2). Although maternal death due to ectopic 
pregnancy has recently decreased, it is still 
a leading cause of mortality in the first 
trimester (3). Therefore, early management 
of ectopic pregnancy is very important. 
Expectant management, surgical, and 
medical strategies are alternative 
treatments for EP (4). Methotrexate as a 
folic acid antagonist is routinely used in 
medical treatment of EP (5, 6). It has been 
shown that Methotrexate is safe and its 
efficacy is similar to that of surgical 
interventions (7, 8). However, the success 
rate of Methotrexate has been reported to 
vary from 47% to 95% (9, 10). Various 
prognostic factors have been proposed for 
predicting treatment response to 
methotrexate including serum 
concentration of β-subunit of human 
chorionic gonadotropin (β-hCG), ectopic 
pregnancy diameter and etc. (11-13). 
However, no consensus has been reached 
on many of these factors.  
Several studies have found association 
between lower pre-treatment 
concentrations of β-hCG with high success 
rates of methotrexate in management of EP 
(14, 15). However, no comprehensive 
conclusion has been made about the 
prognostic value of β-hCG in treatment 
response to methotrexate. Therefore, the 
study aimed to assess this subject through 
a systematic review and meta-analysis.  
2- MATERIALS AND METHODS 
2-1. Search strategy 
The study was conducted according to 
the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses 
(PRISMA) statement (16). A literature 
search using a structured predefined search 
string was performed in online databases 
(Medline, SCOPUS, Cochrane library, 
and EMBASE databases) with no temporal 
restrictions. The search was limited to 
studying human participants. Validated 
combinations of MeSH and EMTREE 
terms and key words were used.  
These search terms in PubMed were: 
"Pregnancy, Ectopic"[Mesh] OR "Ectopic 
Pregnancies"[tiab] OR "Pregnancies, 
Ectopic"[tiab] OR "Pregnancy, 
Interstitial"[Mesh] OR "Interstitial 
Pregnancy"[tiab] OR "Pregnancy, 
Extrauterine"[tiab] OR "Pregnancy, 
Abdominal"[tiab] OR "Extrauterine 
Pregnancy"[tiab] OR "Extrauterine 
Pregnancies"[tiab] OR "Pregnancy, 
Cornual"[tiab] OR "Pregnancy, 
Ovarian"[tiab] OR "Pregnancy, 
Angular"[tiab] OR "Pregnancy, 
Heterotopic"[tiab] OR "Ectopic 
Pregnancy"[tiab] OR "tubular 
pregnancy"[tiab] OR "pregnancy"[tiab] 
OR "Chorionic Gonadotropin, beta 
Subunit, Human"[Mesh] OR "Chorionic 
Gonadotropin"[tiab] OR "Beta-hCG"[tiab] 
OR "β-hCG"[tiab] OR "Human Chorionic 
Gonadotropin"[tiab] AND 
"Methotrexate"[Mesh] OR 
"Amethopterin"[tiab] OR "Methotrexate, 
(D)-Isomer"[tiab] OR "Methotrexate, 
(DL)-Isomer"[tiab] OR "Mexate"[tiab] OR 
"Methotrexate Sodium"[tiab] OR "Sodium, 
Methotrexate"[tiab] OR "Methotrexate, 
Disodium Salt"[tiab] OR "Methotrexate, 
Sodium Salt"[tiab] OR "Methotrexate 
Hydrate"[tiab] OR "Hydrate, 
Methotrexate"[tiab] OR "Methotrexate, 
Dicesium Salt"[tiab] OR "Dicesium Salt 
Methotrexate"[tiab]. 
In addition, we checked cross-references 
of all articles meeting the inclusion criteria 
and previous reviews to identify additional 
articles. Moreover, non-indexed reports 
were also searched in Google search 
engine and Google scholar. The authors of 
the related articles were also asked to 
provide any unpublished data that were not 
registered or any unpublished 
dissertations. The ProQuest database was 
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also precisely searched for related theses. 
In cases where data were not available 
online, the corresponding author of article 
was contacted. A reminder was also sent to 
the author after one week of no response. 
If no answer was received, the co-authors 
were contacted through social networks 
such as ResearchGate and LinkedIn. We 
performed this wide search to include the 
maximum number of relevant patients. 
Also, contacting the authors of all the 
studies that met the inclusion criteria was 
attempted and unpublished data and 
abstracts were requested. 
2-2. Selection of study and data 
extraction 
All potentially eligible original papers 
were independently summarized by two 
authors (M.Y., P.G). A third author (S.S) 
was consulted in case of disagreement. We 
included all cohort studies, case-control 
studies, and clinical trials of ectopic 
pregnancy patients treated by methotrexate 
from all age groups. These studies should 
have measured serum or plasma 
concentrations of β-hCG at least before 
intervention and should have assessed the 
treatment outcome. The diagnosis of 
ectopic pregnancy should have been 
confirmed based on ultrasound assessment 
or presence of elevated level of β-hCG. 
Animal studies, lack of comparison results 
based on β-hCG level in treated and 
control groups, and poor quality of study 
were defined as exclusion criteria. 
Data were extracted independently by two 
reviewers using a standardized data 
abstraction form. We collected information 
related to study design, patient 
characteristics (age, gestational age), 
protocol of treatment (single or multiple 
dose), type of drug administration 
(intramuscular, intravenous, local), sample 
size, data collection methods (prospective 
or retrospective), sampling (consecutive or 
convenience), success rate and failure rate, 
laboratory aspects of β-hCG testing (type 
of assay used, timing of sampling), 
treatment response criteria, β-hCG cut off 
value, and outcome of treatment. We 
contacted authors for clarification about 
the missing data.  
3-2. Quality assessment 
The quality of the eligible studies was 
assessed using Methods Guide for 
Effectiveness and Comparative 
Effectiveness Reviews developed by 
Agency for Healthcare Research and 
Quality (AHRO) (17). Two reviewers 
(M.Y., P.G.) independently reviewed and 
rated of the papers into three levels of 
"good", "fair", or "poor". Quality 
assessment was carried out based on 
impact of methodological quality on the 
reported outcomes, accounting for study 
design, and presence of bias (performance, 
recording, and reporting). Inter-rater 
reliability between two reviewers was 
87%. Disagreements were discussed with a 
third reviewer. 
4-2. Statistical analysis 
Statistical analysis was performed using 
the Stata software, version 12.0 
(Stata Corp, College Station, TX, USA). 
Data were extracted and mean and 
standard deviation value of serum β-hCG 
were recorded. Effect sizes were calculated 
as the standardized mean difference 
(SMD) with 95% confidence interval (CI) 
using Hedges’ g. The authors were 
contacted if the paper did not report mean 
values or standard deviations (SD). If they 
did not respond, estimation methods were 
used to calculate the mean and SD (18). 
Sistrom and Mergo method was used in 
cases where the information were reported 
as graphs (19). 
Statistical heterogeneity was measured 
using the I2 and χ2 –tests. For this purpose 
P < 0.10 represented a significant 
statistical heterogeneity (20). Random 
effects models were generated for data 
analysis because the test of heterogeneity 
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was significant. In addition screening 
performance characteristics (area under the 
curve, sensitivity, specificity, prognostic 
odds ratio) of serum β-hCG level were 
assessed. For this purpose, Patients were 
divided into two groups: successful 
response to treatment and failure. 
Treatment failure was defined as a drop of 
less than 15% in β-hCG concentration 
compared to the baseline value after one 
week or failure result yielded from 
ultrasound examination. Then, the cut off 
value of β-hCG level were recorded. Based 
on this value, data were summarized as 
true positive (true prediction of response to 
treatment), true negative (true prediction of 
treatment failure), false positive (false 
prediction of response to treatment), and 
false negative (false prediction of 
treatment failure) values. Finally, area 
under the curve, sensitivity, specificity, 
and prognostic odds ratio of serum β-hCG 
level in different cut points were 
evaluated. 
Publication bias was assessed using funnel 
plots, formal Egger's and Begg's tests (21) 
and Deeks funnel plot asymmetry test (22). 
A two sided P-value <0.05 was considered 
as statistically significant.  
3- RESULTS 
3-1. The characteristics of included 
studies 
A total of 4,630 non-duplicate articles 
were identified using search strategies 
from which 713 potentially relevant papers 
were screened. Finally, 155 studies were 
found to be eligible and 51 full-text 
articles (5, 9-13, 23-67) were included in 
meta-analysis and were studied in details 
(Figure.1). Table.1 summarizes these 
articles. A study compromised two 
separate experiment (30). Overall, 5,599 
women with EPs were included. The mean 
and standard deviation of pre-treatment β-
hCG level was reported in 50 studies.  In 
addition, these measurements were done in 
the fourth day in 11 studies (12, 38, 43, 45, 
54-57, 63, 65, 67) and in the seventh day 
in 9 (10, 12, 38, 43, 55, 57, 63, 65, 67). 
The prognostic value of β-hCG in 
treatment response of EP to methotrexate 
was reported in 20 articles (10-13, 24-26, 
30, 31, 34, 37, 39, 44, 45, 54, 57, 58, 63, 
64, 66). Overall, treatment success rate of 
methotrexate was found to be 84% (95% 
CI: 84% to 85%). 
3-2. Heterogeneity and publication bias 
SMD of serum β-hCG levels were found to 
be heterogeneous between the two groups 
at the temporal cut offs of before 
intervention (I2=87.6%; P<0.001), fourth 
day (I2=90.2%; P<0.001) and seventh day 
(I2=90.7%; P<0.001). Heterogeneity was 
also observed in the assessment of serum 
β-hCG level screening performance 
characteristics in predicting treatment 
response (Table.2). Therefore, we used 
random effect model in all analyses. No 
publication bias was found among the 
included studies (Table.2).  
3-3. Meta-analysis 
3-3-1. Relation between serum β-hCG 
level and treatment response to 
methotrexate 
Forty nine studies were found from which 
mean and standard deviation values of 
serum β-hCG level was extracted (5, 9-13, 
23, 24, 26-67). A total of 4,334 successful 
treatment cases and 1,073 failure cases 
were assessed. According to our analysis, 
there was negative association between 
serum β-hCG level and the treatment 
response before (SMD= -1.10, 95% CI: -
1.39 to -0.88), four days (SMD= -1.97, 
95% CI: -2.59 to -1.35), and seven days 
(SMD= -1.92, 95% CI: -2.66 to -1.18) 
after intervention (Figure.2). 
3-3-2. Performance characteristics of β-
hCG in predicting response to 
methotrexate treatment 
Table.2 shows the area under the curve, 
sensitivity, specificity, and prognostic odds 
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ratio for serum β-hCG concentrations 
(before intervention level) of 1000 to 5000 
mIU/mL. Pooled sensitivity, specificity, 
and prognostic odds ratio of β-hCG in the 
1000 mIU/mL cut off were 0.85 (0.72-
0.93), 0.51 (0.34-0.67), and 6.0 (4.0-9.0), 
respectively. These values for the 2000 
mIU/mL cut off were 0.75 (0.65-0.82), 
0.68 (0.58-0.82), and 6.0 (5.0-8.0), 
respectively. The performance 
characteristics for different cut offs are 
presented in Table.2. Although the best 
prognostic odds ratio was observed in the 
4,000 mIU/mL cut off, these pooled values 
was calculated from 4 studies. Therefore, 
based on the sensitivity and specificity, the 
2000 mIU/mL concentration could be 
considered as a rational cut off point in 
predicting treatment response of ectopic 
pregnancy to methotrexate. 
4- DISCUSSION 
To the best of our knowledge, the 
present study is the first quantitative meta-
analytic approach to review all available 
evidence regarding the value of serum β-
hCG levels in predicting treatment 
response of ectopic pregnancy to 
methotrexate. This meta-analysis showed 
that success of methotrexate treatment in 
the management of ectopic pregnancy may 
depend on pre-treatment β-hCG 
concentration. The lower the serum 
concentration of β-hCG, the higher the 
chance of successful methotrexate 
treatment. We found significant 
heterogeneity between the eligible studies. 
Therefore, a subgroup analysis was 
performed to assess its possible sources. 
However, the source of heterogeneity was 
not detected. The performance 
characteristics of β-hCG in predicting 
response to methotrexate treatment were 
also assessed in several cut off points 
(Table. 2). The area under the curve of β-
hCG in different cut offs ranged from 0.76 
to 0.81, which indicative of a moderate 
predictive value. Based on the prognostic 
odds ratio, sensitivity, and specificity, we 
suggest β-hCG concentration of 2000 
mIU/mL as a rational cut off point for 
predicting treatment response. Our results 
showed higher likelihood of therapeutic 
success in patients with β-hCG 
concentrations lower than 2000 mIU/mL.  
Previous studies reported the initial β-hCG 
concentration properly predict treatment 
success with a single dose of methotrexate. 
Barnhart et al. showed the difference in 
success rate of single dose and multi dose 
treatment protocol are affected by β-hCG 
concentration (68). In their meta-analysis, 
success rate of multi dose management of 
methotrexate 
was estimated to be 1.96 times higher than 
the use of single dose regime. This value 
reached to 2.34 after adjusting the analysis 
for β-hCG levels. In addition, Bachman 
and Barnhart in a narrative review stated 
that there is no established true cut-off for 
initial β-hCG levels for predicting outcome 
of methotrexate therapy (69). In the 
present study we suggest β-hCG 
concentration of 2000 mIU/mL as a 
rational cut off point for predicting 
treatment response of EP to Methotrexate. 
 Three facts have improved the quality of 
the present study. First we assessed the 
confirmed cases of ectopic pregnancy and 
excluded patients with suspected diagnosis 
from our analysis. Second, we calculated 
SMDs as the effect size estimate using 
Hedges' g to be able to make comparisons 
across the articles and to correct for the 
bias caused by the small sample size. In 
addition we included studies with a 
minimum of 10 samples. Third, we 
performed subgroup analysis stratified by 
β-hCG assessment time (days 0, 4 and 
seven) and β-hCG cut off points, since 
heterogeneity is expected to affect meta-
analyses of observational studies. 
Moreover, we designed an extensive 
search and used a comprehensive 
analytical approach which allowed 
inclusion of studies presenting not only 
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means and standard deviations, but also 
medians and ranges. 
4-1. Study limitations  
The present review and meta-analysis 
has a number of potential limitations. First, 
there is the issue of heterogeneity between 
the studies. Therefore, a random effects 
model was used which yielded more 
conservative results. Second, absence of 
adjustment for potential confounding 
factors that might have affected the serum 
levels of β-hCG. 
5- CONCLUSIONS 
The present meta-analysis showed that 
low serum β-hCG concentration may be 
able to predict success of methotrexate 
treatment in management of EP. Our 
results showed higher likelihood of 
therapeutic success in patients with β-hCG 
concentrations lower than 2000 mIU/mL. 
However, the pooled sensitivity and 
specificity of β-hCG in this cut off point 
were 0.75 and 0.68, which indicates that β-
hCG concentration alone cannot properly 
predict the treatment outcome. We suggest 
that the future studies design a predictive 
model, in which β-hCG concentration is 
entered along with other factors. 
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Fig.1: PRISMA Flowchart 
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 Table-1: The characteristics of eligible studies 
Author Year Age Gestational age Type of injection Treatment protocol Success rate (n) Failure rate (n) 
Ransom et al. 1994 32 NR IM Single 15 6 
Lipscomb et al. 1999 26 NR IM Single 320 30 
Tawfiq et al. 2000 27-42 NR IM Single 44 16 
Olofsson et al. 2001 29.6 42 IM Single 20 6 
Gamzu et al. 2002 31 NR IM Single 44 6 
Lipscomb et al. 2002 24.5 NR IM Single 18 3 
Natale et al. 2002 NR 41 IM Single 39 11 
Gervaise et al.* 2003 31.1 48 IM Single 54 19 
Gervaise et al.* 2003 30.6 47.6 Local Single 43 4 
Nazac et al. 2003 30.7 NR IM Single 109 28 
Potter et al. 2003 NR NR IM Single 69 12 
Erdem et al. 2004 NR NR IM Single 30 4 
Kumtepe et al. 2004 28.2 NR IM Single 18 11 
Lipscomb et al. 2004 27 NR IM Single 448 47 
Bixby et al. 2005 29 NR IM Single 45 17 
Cassik et al. 2005 49 NR Local/IV Single 35 5 
Cho et al. 2006 NR NR IM Single 33 6 
Gabbur et al. 2006 32 NR IM Single 60 23 
Soliman et al. 2006 27.1 56.8 IM Single 26 4 
Srivichai et al. 2006 27 51.2 IM Single 96 10 
Behnamfar et al. 2007 27.8 NR IM Single 32 9 
Kirk et al. 2007 31.5 43 IM Single 47 22 
Skandar et al. 2007 29.2 NR IM Single 66 4 
Lipscomb et al. 2009 25.9 NR IM Single 60 13 
Nowak-Markwitz et al. 2009 30 42 IM Single 53 11 
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Balci et al. 2010 30.7 46.2 IM Multiple 230 64 
Butts et al. 2010 27 41 IM Single 160 29 
Rabischong et al. 2010 15-45 NR IM Single 316 103 
Jiang et al. 2011 34.46 50.22 IM Single 42 3 
Kasum et al. 2012 NR NR IM Single 32 3 
Sagiv et al. 2012 30.3 NR IM Single 167 71 
Kimiaei et al. 2013 31.4 58.1 IM Single 165 20 
Krissi et al. 2013 31.5 NR IM Single 92 10 
Ustunyurt et al. 2013 27.5 NR IM Single 63 24 
Avcioglu et al. 2014 30.5 NR IM both 68 29 
Azargoon et al. 2014 29.8 NR IM Single 54 16 
Cohen et al. 2014 30 NR IM Second 58 15 
Cohen et al. 2014 31 47 IM Single 356 53 
de Waard et al. 2014 24.4 NR IM Single 59 65 
Gnisci et al. 2014 32 NR IM Single 69 24 
Helmy et al. 2014 30.57 NR IM Single 162 36 
Hiersch et al. 2014 32.6 46.1 IM Single 12 5 
Kilic et al. 2014 30.72 47 IM Single 67 32 
Poon et al. 2014 33 NR IM Single 17 2 
Sinprasertnavin et al. 2014 25.3 47 IM Single 48 48 
Vaswani et al. 2014 28.7 NR IM Single 30 10 
Wu et al. 2014 32.3 NR IM Single 99 19 
Alsammani et al. 2015 29.6 45 IM Single 66 43 
Cok et al. 2015 33.7 46 IM Single 11 7 
Orozco et al. 2015 31.4 NR IM Single 111 15 
Peng et al. 2015 32.6 56 Local/IV Single 71 33 
Shaamash et al. 2015 NR NR IM Single 38 11 
*This study had two separate experiment. NR: not reported; IM: intramuscular; IV: intravenous. 
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 Table-2: Primary meta-analyses of βhCG level in patients with ectopic pregnancy. 
Characteristic 
Number of included 
studies 
Number of subjects 
(Success/Failure) 
P-value 
aon bias)(publicati 
P (heterogeneity %) Effect size (95% CI) P-value 
βhCG level  
Day 0 50 4334/1073 0.21 <0.001 (87.6) 0.88)- -1.39-( b1.10- <0.001 
Day 4 11 603/207 0.22 <0.001 (90.2) 1.35)- -2.59-( b1.97- <0.001 
Day 7 9 499/160 0.06 <0.001 (90.7) 1.18)- -2.66-( b1.92- <0.001 
Area under curve 
Cut off (mIU/mL)       
1000 11 1257/293 0.88 <0.001 (100.0) 0.76 (0.72-0.79) NA 
2000 18 1567/386 0.89 <0.001 (99.0) 0.77 (0.73-0.81) NA 
3000 5 331/120 0.47 <0.001 (94.0) 0.78 (0.74-0.82) NA 
4000 4 208/88 0.42 <0.001 (92.0) 0.81 (0.78-0.85) NA 
5000 8 789/195 0.37 <0.001 (96.0) 0.81 (0.77-0.84) NA 
Sensitivity 
Cut off (mIU/mL)       
1000 11 1257/293 0.88 <0.001 (100.0) 0.85 (0.72-0.93) NA 
2000 18 1567/386 0.89 <0.001 (99.0) 0.75 (0.65-0.82) NA 
3000 5 331/120 0.47 <0.001 (94.0) 0.68 (0.37-0.85) NA 
4000 4 208/88 0.42 <0.001 (92.0) 0.63 (0.28-0.88) NA 
5000 8 789/195 0.37 <0.001 (96.0) 0.36 (0.19-0.58) NA 
Specificity 
Cut off (mIU/mL)       
1000 11 1257/293 0.88 <0.001 (100.0) 0.51 (0.34-0.67) NA 
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2000 18 1567/386 0.89 <0.001 (99.0) 0.68 (0.58-0.82) NA 
3000 5 331/120 0.47 <0.001 (94.0) 0.78 (0.58-0.90) NA 
4000 4 208/88 0.42 <0.001 (92.0) 0.82 (0.61-0.93) NA 
5000 8 789/195 0.37 <0.001 (96.0) 0.89 (0.81-0.93) NA 
Prognostic odds ratio 
Cut off (mIU/mL)       
1000 11 1257/293 0.88 <0.001 (100.0) 6.0 (4.0-9.0) NA 
2000 18 1567/386 0.89 <0.001 (99.0) 6.0 (5.0-8.0) NA 
3000 5 331/120 0.47 <0.001 (94.0) 7.0 (4.0-12.0) NA 
4000 4 208/88 0.42 <0.001 (92.0) 8.0 (3.0-23.0) NA 
5000 8 789/195 0.37 <0.001 (96.0) 4.0 (2.0-9.0) NA 
aBegg’s and Egger’s test for standardize mean difference and Deeks funnel plot asymmetry test for  performance characteristics values. bStandardized mean difference.  
CI: Confidence interval; NA: Not applicable. 
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NOTE: Weights are from random effects analysis
Overall  (I-squared = 87.6%, p = 0.000)
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Fig.2: Standardize mean difference (SMD) of serum β-subunit of human chorionic gonadotropin level for predicting treatment response of ectopic pregnancy 
to methotrexate 
